Abstract
The last 7 years have seen a growing number of cost-effectiveness studies demonstrating that screening people for signs of depression and the subsequent provision of psychological therapy to prevent the onset of depressive disorder is a cost-effective intervention. Many of the studies have expressed outcomes generically, either as quality-adjusted life-years or disability-adjusted life-years, and reported results well below conventional thresholds of 'value for money.' However, such interventions are still not routinely delivered in many healthcare systems, suggesting a 'translational' gap between evidence and practice. Future research needs to better integrate comprehensive economic evaluation indices into study designs, such as broad assessment of costs and impacts, including non-health impacts, to gain an accurate insight into the broader economic benefits of such interventions. Furthermore, a focus on interventions aimed at children and adolescents, which can demonstrate impact into adulthood, are likely to be highly favourable, both clinically and economically.
| Original language | English |
|---|---|
| Pages (from-to) | 237-242 |
| Number of pages | 6 |
| Journal | Expert Review of Pharmacoeconomics and Outcomes Research |
| Volume | 13 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Apr 2013 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- cost-effectiveness
- depression
- economic evaluation
- prevention
- value for money
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver